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PID8
COSTS OF HEALTH CARE FOR HEPATITIS
C-INFECTED MEMBERS IN A MANAGED
CARE ORGANIZATION (MCO)
Schaffer M1, Phillips AL2, Mansukani S1
1Health Partners, Inc, Philadelphia, PA, USA; 2Thomas Jefferson 
University, Philadelphia, PA, USA
The current literature provides limited information about
the cost-burden of Hepatitis C. OBJECTIVES: To iden-
tify all medical and pharmacy costs accrued by members
with Hepatitis C in a Medicaid MCO during 1999.
METHODS: Hepatitis C-infected patients were identified
from a database of continuously enrolled members from
an inner-city Medicaid MCO in Philadelphia during
1999 using ICD-9 codes indicative of Hepatitis C. Medi-
cal and pharmacy claims for these identified members
during this study period were obtained and analyzed. A
subanalysis comparing patients prescribed combination
ribavirin/interferon alfa-2b therapy with patients not pre-
scribed combination therapy was performed. Costs were
reported as reimbursements paid for medical claims and
pharmacy claims (AWP—14.5%). RESULTS: From a co-
hort of 73,869 members, 395 members (0.535%) met in-
clusion criteria for Hepatitis C. The mean age was 46.5
years (SD  9.5; range  4–81) and 213 (53.9%) were
male. These members had 17,507 medical claims result-
ing in payments of $4,075,082. Inpatient hospital ser-
vices accounted for 48% of these costs. There were
27,681 pharmacy claims that totaled $1,495,096. Sixty
patients received combination therapy, which totaled
$375,468 in pharmacy claims (n  444). Comparing pa-
tients prescribed combination therapy and patients not
prescribed combination therapy, medical costs were
$2,580/member and $11,702/member, respectively. In
addition, pharmacy costs were $8,610/member and
$2,920/member, respectively. Total costs in 1999 for pa-
tients prescribed combination therapy was $11,190/
member and for patients not prescribed combination
therapy was $14,622/member. These results were not ad-
justed for disease severity. CONCLUSIONS: Hepatitis C
is a very costly disease. Total health care costs to this
Medicaid MCO during 1999 for the 395 members identi-
fied with Hepatitis C exceeded $5.5 million. In addition,
total costs were less for members prescribed combination
ribavirin/interferon alfa-2b therapy compared with mem-
bers not prescribed combination therapy. Further investi-
gation is needed to explain the observed differences in
health care expenditures between these two populations.
PID9
COST-EFFECTIVENESS OF INTERFERON ALFA 
THERAPY FOR CHRONIC HEPATITIS C 
WITH CIRRHOSIS
Hisashige A, Katayama T, Mikasa H
University of Tokushima, School of Medicine, Tokushima, Japan
OBJECTIVE: To estimate the lifetime benefits and costs
of interferon alfa therapy for active hepatitis C with cir-
rhosis (HC), cost-effective analysis was carried out.
METHODS: Cost-effectiveness analysis (CEA) and cost-
utility analysis (CUA) were carried out to estimate the
lifetime benefits and costs of interferon alfa therapy (IFA)
for HC. A Markov model base on a randomized con-
trolled trial was developed. As a comparator, conven-
tional therapy (CV) was used. A societal viewpoint was
adopted for the estimation of costs, and both direct and
indirect costs were evaluated. A Monte Carlo simulation
was done to evaluate a confidence interval of cost-effec-
tiveness or cost-utility ratio. Quality of life (utility) was
measured by a time-trade off method among HC pa-
tients. RESULTS: At lifetime follow-up among 40 years
of men, expected life years (15.2 years) for IFA were
longer than those (9.0 years) for CT. Moreover, expected
QALYs (9.86) for IFA were longer than those (5.30) for
CT. On the other hand, expected costs ($548,500) for
IFA were higher than those ($459,000) for CT. The in-
cremental cost per life-year gained for IFA was $4,900
(discount rate of cost and effectiveness: 5%). The incre-
mental cost per QALY gained was $6,240. Sensitivity
analysis for age, costs, and health outcomes confirmed
robustness of these results. CONCLUSION: On the basis
of this analysis, IFA for HC should prolong length and
quality of life at a reasonable incremental costs, from a
societal perspective.
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EFFECTS OF LINEZOLID ON HOSPITAL LENGTH 
OF STAY IN METHICILLIN-RESISTANT 
STAPHYLOCOCCUS INFECTIONS ESTIMATED 
FROM MULTIVARIATE SURVIVAL ANALYSIS
Willke RJ1, Li ZJ2, Glick H3, Rittenhouse BE1, Hafkin B4
1Pharmacia, Peapack, NJ, USA; 2Pharmacia Corporation, 
Kalamazoo, MI, USA; 3University of Pennsylvania, Philadelphia, 
PA, USA; 4Pharmacia Corporation, Portage, MI, USA
OBJECTIVES: To estimate differences in adjusted hospi-
tal length of stay (LOS) between linezolid and vancomycin
using multivariate survival analysis. Linezolid’s bioequivalent
IV and oral formulations may enable earlier hospital dis-
charge compared to vancomycin treatment. METHODS:
460 hospitalized patients with suspected/confirmed me-
thicillin-resistant Staphylococcus infections were treated
with either linezolid (LZD) or vancomycin (VAN) in a
randomized controlled trial. Covariate imbalances be-
tween treatment groups were tested using t-tests and chi-
square tests. Multivariate Cox proportional hazards and
several parametric models for LOS were tested for best fit
using the Akaike Information Criteria and log-likelihood
ratio statistics. The Cox proportional hazards assump-
tion was rejected (p  .05); log-logistic survival models
fit best. The log-logistic estimates are used to create two
alternative adjusted survivorship functions, one based on
individual corrections to LOS (Individual correction),
and the other based on means of the predicted survivor-
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ship function for each individual (Mean survivorship).
Adjusted LOS at quartiles of % discharged for each func-
tion was compared with unadjusted LOS using Kaplan-
Meier method. RESULTS: Hospital unit type at random-
ization and number of comorbidities both differed signif-
icantly between groups and significantly affected LOS.
With covariate controls in the log-logistic model, line-
zolid treatment significantly reduced LOS (p  .04). Ad-
justed/unadjusted LOS at quartiles of % discharged were:
CONCLUSIONS: When adjusted for covariate differ-
ences, median LOS for linezolid patients was at least 2
days shorter than for vancomycin patients. Other differ-
ences in the LOS distribution are evident and may be im-
portant to decision-makers but off-median estimates may
be sensitive to the adjustment method used. Method-
ologic considerations are explored further.
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PEGYLATED (40KDA) INTERFERON ALFA-2A 
(PEGASYS®) SIGNIFICANTLY IMPROVES 
TOLERABILITY, QUALITY OF LIFE, AND WORK 
PRODUCTIVITY IN PATIENTS WITH CHRONIC 
HEPATITIS C
Imperial J1, Thuluvath P2, Perrillo RP3, Rothstein KD4,
Poulios NS5, Pappas SC5, Ackermann SP5, Doerschuk BS5
1Stanford Medical School, Palo Alto, CA, USA; 2John Hopkins 
Hospital, Baltimore, MD, USA; 3Ochsner Clinic, New Orleans, 
LA, USA; 4Albert Einstein Medical Center, Philadelphia, PA, 
USA; 5Roche Laboratories Inc, Nutley, NJ, USA
BACKGROUND: Several studies have demonstrated the
negative impact of chronic hepatitis C (CHC) and respec-
tive treatments on patient health-related quality of life.
Studies suggest PEGASYS provides an improved sus-
tained virological response compared with interferon (IFN)
monotherapy (30–39% vs 10–19%) and may provide
safety, quality of life (QoL), and work productivity bene-
fits compared with standard interferon/ribavirin (IFN/RBV,
REBETRONTM) combination therapy. OBJECTIVE: To
compare the safety and tolerability of treatment with PE-
GASYS vs REBETRON in previously untreated patients
with chronic hepatitis C (CHC). METHODS: A 72-week,
multicenter study randomized 412 patients to PEGASYS
180 g qw or REBETRON (IFN-26 3 MIU tiw  RBU
1000-1200 mg qd). Tolerability was assessed by the Hep-
atitis Quality of Life Questionnaire (HQLQ, assessed at
weeks 4, 12, 24, 48, 60, and 72; SF-36 plus 4 Hepatitis-
specific domains) and the Work Productivity and Activity
Impairment (WPAI) instrument. RESULTS: After 12
%
discharged






LZD VAN LZD VAN LZD VAN
25 6 10 6 9 6 8
50 (median) 14 16 13 16 14 15
75 26 28 28 29 29 29
weeks of treatment, HCV-RNA was negative in 46.8%
of PEGASYS and 50.3% of REBETRON patients. Pa-
tients on PEGASYS showed a clinically significant differ-
ence compared to REBETRON in several AEs: anemia
(2.0% vs 32.4%), dyspnea (9.5% vs 18.1%), pruritus
(6.7% vs 17.5%). At weeks 4 and 12, patients on PEGA-
SYS compared to REBETRON had significantly better
work productivity (Estimated Wkly Work Productivity
Lost: $32.10, PEGASYS; $86.60, REBETRON) in 7 of 7
domains. Week 4 and 12 HQLQ assessments indicated
patients on PEGASYS vs those on REBETRON had clini-
cally and statistically better QoL scores in 8 of 8 SF-36
domains, both physical and mental summary scores, and
4 CHC-specific domains (P  0.05). CONCLUSIONS: The
12-week data demonstrate that patients treated with PE-
GASYS had a superior tolerance to therapy, were more
productive as measured by the WPAI, and had better
health related quality of life profiles compared with pa-
tients treated with REBETRON, while maintaining simi-
lar virological response.
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AVERTING FUTURE AIDS CASES:
MODELING COSTS OF INTERVENTIONS WITH
OUT-OF-TREATMENT SUBSTANCE ABUSERS
Richter A, Loomis BR, Wechsberg WM
Research Triangle Institute, Research Triangle Park, NC, USA
OBJECTIVE: The North Carolina Cooperative Agree-
ment (NCCoOp) for AIDS Intervention Research imple-
mented an AIDS intervention in an urban, high-risk, pri-
marily African-American, crack and injection drug-using
population. Estimated costs for the standard intervention
are $242 per person. How many future AIDS cases will
be averted by making this expenditure? METHODS: We
constructed an epidemic model to assess the long-term
impacts of intervention related changes on HIV incidence
and prevalence. Our model is a dynamic compartment
model focusing on 8 distinct sexual and drug use risk
groups within the community. Cost data are available
from existing intervention analyses. RESULTS: 778 per-
sons were enrolled in the NCCoOp intervention in Wake
and Durham counties, NC. Of these, 80 (11.5%) were
HIV positive. Using data collected prior to intervention,
our model predicts that HIV prevalence will rise to 18%
of the NCCoOp population in five years. The epidemic is
driven predominantly by high-frequency needle users
(HFNU), primary needle users (PNU), and primary crack
users (PCU) who account for 79% of new infections over
this time period. Using data collected after intervention,
our model predicts HIV prevalence will decline to 7% of
the NCCoOp population in five years. However, HFNU,
PNU, and PCU account for 89% of new infections in this
case. Risky drug use and sexual behaviors were dramati-
cally reduced by intervention and this accounts for most
of the reduction in HIV prevalence. Other factors influ-
encing the reduction in HIV prevalence are AIDS mortal-
ity and growth in the drug using population. CONCLU-
